Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, which resulted in the new company Novartis. Mipharm was founded by a group of ex-managers from Novartis through a spin-off of the manufacturing site Via Quaranta, previously owned by Sandoz, located in Milan.
In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital.
Today, Mipharm is one of the most valuable third-party manufacturing and new product development sites...in Italy, and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).
Service Offerings:
Pre-formulation studies
Comprehensive design and formulation studies
Commercial Manufacturing
Preparation of validation batches
Optimization of manufacturing processes
Comprehensive galenical and analytical documentation
Technical dossiers for registration
Chemical Testing of raw materials and finished products
Microbial Testing of raw materials & Finished products
Testing of packaging Material
Stability Studies per ICH
Development & Validation of Analytical Methods per ICH
